Towards the pharmacotherapy of hairy cell leukaemia

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1523-1533

  Lauria, Francesco ^a   Forconi, Francesco ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Cladribine; HCL; Interferon; Monoclonal antibodies; Pentostatin; Splenectomy

Indexed keywords

ALPHA INTERFERON; ANDROGEN; BETA INTERFERON; BL 22; CD20 ANTIGEN; CD22 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INTERLEUKIN 2 RECEPTOR; LITHIUM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD22; NUCLEOSIDE DERIVATIVE; PARACETAMOL; PENTOSTATIN; PURINE DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT IMMUNOTOXIN; RITUXIMAB; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BONE PAIN; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHRONIC LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DEPRESSION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIRY CELL LEUKEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOTOXICITY; INFECTION; KIDNEY DYSFUNCTION; LETHARGY; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MOOD DISORDER; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PANCYTOPENIA; PROGNOSIS; REVIEW; SPLENECTOMY; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, HAIRY CELL; PURINES; TIME FACTORS;

EID: 3543076504     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1523     Document Type: Review

References (79)

1. BOURONCLE BA, WISEMAN BK, DOAN CA: Leukemic reticuloendotheliosis. Blood (1958) 13(7):609-630.
2. QUESADA JR, REUBEN J, MANNING JT, HERSH EM, GUTTERMAN JU: Alpha interferon for induction of remission in hairy-cell Leukemia. N. Engl. J. Med. (1984) 310(1):15-18.
3. ZAKARIJA A, PETERSON LC, TALLMAN MS: Splenectomy and treatments of historical interest. Best Pract. Res. Clin. Haematol. (2003) 16(1):57-68.
4. MINTZ U, GOLOMB HM: Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res. (1979) 39(7 Pt 1):2366-2370.
5. JANSEN J, HERMANS J, REMME J, DEN OTTOLANDER GJ, CARDOZO PL: Hairy cell leukaemia. Clinical features and effect of splenectomy. Scand. J. Haematol. (1978) 21(1):60-71.
6. GOLOMB HM, CATOVSKY D, GOLDE DW: Hairy cell leukemia: a five-year update on seventy-one patients. Ann. Intern. Med. (1983) 99(4):485-486.
7. JANSEN J, HERMANS J: Clinical staging system for hairy-cell Leukemia. Blood (1982) 60(3):571-577.
8. GOLOMB HM, VARDIMAN JW: Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood (1983) 61(2):349-352.
9. CASTRO-MALASPINA H, NAJEAN Y, FLANDRIN G: Erythrokinetic studies in hairy-cell leukaemia. Br. J. Haematol. (1979) 42(2):189-197.
10. SMALLEY RV, CONNORS J, TUTTLE RL, ANDERSON S, ROBINSON W, WHISNANT JK: Splenectomy versus alpha interferon: a randomized study in patients with previously untreated hairy cell Leukemia. Am. J. Hematol. (1992) 41(1):13-18.
11. NG JP, HOGG RB, CUMMING RL, MCCALLION J, CATOVSKY D: Primary splenic hairy cell leukaemia: a case report and review of the literature. Eur. J. Haematol. (1987) 39(4):349-352.
12. AHMED S, RAI KR: Interferon in the treatment of hairy-cell Leukemia. Best Pract. Res. Clin. Haematol. (2003) 16(1):69-81.
13. VEDANTHAM S, GAMLIEL H, GOLOMB HM: Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res. (1992) 52(5):1056-1066.
14. PLATANIAS LC, PFEFFER LM, BARTON KP, VARDIMAN JW, GOLOMB HM, COLAMONICI OR: Expression of the IFN alpha receptor in hairy cell leukaemia. Br. J. Haematol. (1992) 82(3):541-546.
15. BAKER PK, PETTITT AR, SLUPSKY JR et al.: Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood (2002) 100(2):647-653.
16. SMITH JW, LONGO DL, URBA WJ et al.: Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood (1991) 78(7):1664-1671.
17. RAI KR, DAVEY F, PETERSON B et al.: Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia (1995) 9(7):1116-1120.
18. GOLOMB HM, FEFER A, GOLDE DW et al.: Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. Semin. Oncol. (1988) 15(5 Suppl. 5):7-9.
19. FEDERICO M, FRASSOLDATI A, LAMPARELLI T et al.: Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell Leukemia. Final report from the Italian Cooperative Group for HCL. Ann. Oncol. (1994) 5(8):725-731.
20. BARDAWIL RG, GROVES C, RATAIN MJ, GOLOMB HM, VARDIMAN JW: Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell Leukemia. Am. J. Clin. Pathol. (1986) 85(2):194-201.
21. RATAIN MJ, GOLOMB HM, VARDIMAN JW et al.: Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J. Clin. Oncol. (1988) 6(11):1714-1721.
22. FRASSOLDATI A, LAMPARELLI T, FEDERICO M et al.: Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk. Lymphoma. (1994) 13(3-4):307-316.
23. ZINZANI PL, LAURIA F, RASPADORI D et al.: Results in hairy-cell leukemia patients treated with alpha-interferon: predictive prognostic factors. Eur. J. Haematol. (1992) 49(3):133-137.
24. TROUSSARD X, FLANDRIN G: Hairy cell Leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. Leuk. Lymphoma. (1994) 14(Suppl. 1):99-105.
25. GREVER M, KOPECKY K, FOUCAR MK et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients wiih hairy cell leukemia: an intergroup study. J. Clin. Oncol. (1995) 13(4):974-982.
26. HABERMANN TM, ANDERSEN JW, CASSILETH PA, BENNETT JM, OKEN MM: Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br. J. Haematol. (1992) 80(4):466471.
27. SPIERS AS, PAREKH SJ, BISHOP MB: Hairy-cell leukemia: induction of complete remission with pentostatin (2′ -deoxycoformycin). J. Clin. Oncol. (1984) 2(12):1336-1342.
28. PIRO LD, CARRERA CJ, CARSON DA, BEUTLER E: Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. (1990) 322(16):1117-1121.
29. KANTARJIAN HM, SCHACHNER J, KEATING MJ: Fludarabine therapy in hairy cell Leukemia. Cancer (1991) 67(5):1291-1293.
30. SAVEN A, PIRO L: Newer purine analogues for the treatment of hairy-cell Leukemia. N. Engl. J. Med. (1994) 330(10):691-697.
31. SPIERS AS, MOORE D, CASSILETH PA et al.: Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N. Engl. J. Med. (1987) 316(14):825-830.
32. KRAUT EH, GREVER MR, BOURONCLE BA: Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood (1994) 84(12):4061-4063.
33. DEARDEN CE, MATUTES E, HILDITCH BL, SWANSBURY GJ, CATOVSKY D: Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br. J. Haematol. (1999) 106(2):515-519.
34. CATOVSKY D, MATUTES E, TALAVERA JG et al.: Long term results with 2′deoxycoformycin in hairy cell Leukemia. Leuk. Lymphoma. (1994) 14(Suppl. 1):109-113.
35. RIBEIRO P, BOUAFFIA F, PEAUD PY et al.: Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer (1999) 85(1):65-71.
36. RAFEL M, CERVANTES F, BELTRAN JM et al.: Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer (2000) 88(2):352-357.
37. MALOISEL F, BENBOUBKER L, GARDEMBAS M et al.: Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia (2003) 17(1):45-51.
38. DALAL BI, FREIER L, JOHNSTON JB, MERRY CC, ISRAELS LG: Peripheral blood and bone marrow changes following 2′ -deoxycoformycin therapy in hairy cell Leukemia. Results of 200 weeks' follow-up. Cancer (1989) 63(1):14-22.
39. KRAUT EH, NEFF JC, BOURONCLE BA, GOCHNOUR D, GREVER MR: Immunosuppressive effects of pentostatin. J. Clin. Oncol. (1990) 8(5):848-855.
40. JULIUSSON G, LILIEMARK J: Rapid recovery fiom cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood (1992) 79(4):888-894.
41. HOFFMAN MA, JANSON D, ROSE E, RAI KR: Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J. Clin. Oncol. (1997) 15(3):1138-1142.
42. LAURIA F, RONDELLI D, ZINZANI PL et al.: Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia (1997) 11(5):629-632.
43. CHESON BD, SORENSEN JM, VENA DA et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J. Clin. Oncol. (1998) 16(9):3007-3015.
44. HAKIMIAN D, TALLMAN MS, KILEY C, PETERSON L: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell Leukemia. Blood (1993) 82(6):1798-1802.
45. TALLMAN MS, HAKIMIAN D, RADEMAKER AW et al.: Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood (1996) 88(6):1954-1959.
46. SAVEN A, BURIAN C, KOZIOL JA, PIRO LD: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood (1998) 92(6):1918-1926.
47. GOODMAN GR, BURIAN C, KOZIOL JA, SAVEN A: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol. (2003) 21(5):891-896.
48. LILIEMARK J, ALBERTIONI F, HASSAN M, JULIUSSON G: On the bioavailability of oral and subcutaneous 2-chloro-2′ -deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. (1992) 10(10):1514-1518.
49. VAN DEN NESTE E, DELANNOY A, VANDERCAM B et al.: Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol. (1996) 56(4):235-240.
50. LAURIA F, BOCCHIA M, MAROTTA G, RASPADORI D, ZINZANI PL, RONDELLI D: Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications. Blood (1997) 89(5):1838-1839.
51. SEYMOUR JF, KURZROCK R, FREIREICH EJ, ESTEY EH: 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood (1994) 83(10):2906-2911.
52. RASPADORI D, RONDELLI D, BIRTOLO S et al.: Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment. Leukemia (1999) 13(8):1254-1257.
53. LAURIA F, RONDELLI D, RASPADORI D, BENFENATI D, TURA S: Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Eur. J. Haematol. (1994) 52(1):16-20.
54. MALONEY DG, LILES TM, CZERVINSKI DK et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 84(8):2457-2466.
55. LAURIA F, LENOCI M, ANNINO L et al.: Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica (2001) 86(10):1046-1050.
56. HAGBERG H, LUNDHOLM L: Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br. J. Haematol. (2001) 115(3):609-611.
57. NIEVA J, BETHEL K, SAVEN A: Phase II study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood (2003) 102(3):810-813.
58. THOMAS DA, O'BRIEN S, BUESO-RAMOS C et al.: Rituximab in relapsed or refractory hairy cell leukemia. Blood (2003) 102(12):3906-3911.
59. KREITMAN RJ, PASTAN I: Immunobiological treatments of hairy-cell leukaemia. Best Pract. Res. Clin. Haematol. (2003) 16(1):117-133.
60. KREITMAN RJ, WILSON WH, BERGERON K et al.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. (2001) 345(4):241-247.
61. ROBBINS DH, MARGULIES I, STETLER-STEVENSON M, KREITMAN RJ: Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin. Cancer Res. (2000) 6(2):693-700.
62. KREITMAN RJ, WILSON WH, ROBBINS D et al.: Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood (1999) 94(10):3340-3348.
63. CASSILETH PA, CHEUVART B, SPIERS AS et al.: Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. (1991) 9(2):243-246.
64. SEYMOUR JF, ESTEY EH, KEATING MJ, KURZROCK R: Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia (1995) 9(5):929-932.
65. JACOBS RH, VOKES EE, GOLOMB HM: Second malignancies in hairy cell leukemia. Cancer (1985) 56(6):1462-1467.
66. PAWSON R, A'HERN R, CATOVSKY D: Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Leuk. Lymphoma (1996) 22(1-2):103-106.
67. AU WY, KLASA RJ, GALLAGHER R, LE N, GASCOYNE RD, CONNORS JM: Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood (1998) 92(4):1160-1164.
68. KURZROCK R, STROM SS, ESTEY E et al.: Second cancer risk in hairy cell leukemia: analysis of 350 patients. J. Clin. Oncol. (1997) 15(5):1803-1810.
69. FEDERICO M, ZINZANI PL, FRASSOLDATI A et al.: Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J. Clin. Oncol. (2002) 20(3):638-646.
70. QUESADA JR, HERSH EM, MANNING J et al.: Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood (1986) 68(2):493-497.
71. LAURIA F, FOA R, RASPADORI D et al.: Treatment of hairy-cell leukaemia with alpha-interferon (alpha-IFN). Eur. J. Cancer Clin. Oncol. (1988) 24(2):195-200.
72. BERMAN E, HELLER G, KEMPIN S, GEE T, TRAN LL, CLARKSON B: Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood (1990) 75(4):839-845.
73. JOHNSTON JB, EISENHAUER E, WAINMAN N, CORBETT WE, ZAENTZ SD, DAENINCK PJ: Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin. Oncol. (2000) 27(2 Suppl. 5):32-36.
74. FLINN IW, KOPECKY KJ, FOUCAR MK et al.: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood (2000) 96(9):2981-2986.
75. ESTEY EH, KURZROCK R, KANTARJIAN HM et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood (1992) 79(4):882-887.
76. PIRO LD, ELLISON DJ, SAVEN A: The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk. Lymphoma (1994) 14(Suppl. 1):121-125.
77. JULIUSSON G, HELDAL D, HIPPE E et al.: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol. (1995) 13(4):989-995.
78. JEHN U, BARTL R, DIETZFELBINGER H et al.: Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Ann. Hematol. (1999) 78(3):139-144.
79. LAURIA F, BOCCHIA M, MAROTTA G, RASPADORI D, ZINZANI PL, RONDELLI D: Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica (1999) 84(1):22-25.